Oncocyte Common Stock

The latest common stock for OCX is $390M as of June 2026. That compares with $370M in the prior-year period — up 7.3% year over year. Investors often review this figure alongside Oncocyte's historical trend and sector peers before judging valuation or financial health.

Over the past year, OCX's common stock moved from $370M to $390M — a 7.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Oncocyte's operating scale or balance-sheet position.

A common stock figure of $390M for OCX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting OCX's common stock ($390M), review year-over-year change from $370M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Oncocyte's common stock against similar Technology names. You can also browse sector and industry screens on Stockcircle for a broader set of Technology companies and their key multiples and fundamentals.